Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported Q4 FY26 consolidated revenue of Rs. 37,706 million, up 15.8% YoY, with EBITDA of Rs. 7,626 million (20.2% margin) and PAT of Rs. 3,013 million (7.6% margin). The company highlighted a landmark AbbVie licensing deal for ISB 2001 with USD 700 million upfront payment and potential total deal value of USD 1.925 billion plus tiered royalties. North America revenue surged 136.6% YoY to Rs. 71,390 million for the full year, boosted by the AbbVie deal recognition. India business grew 8.2% with outperformance versus IPM, while Europe and Emerging Markets showed strong growth of 21.4% and 13.7% respectively. The company launched 13 new products in North America and achieved >50% secondary sales growth for RYALTRIS® globally.
The strong Q4 and full-year FY26 results, highlighted by the transformative AbbVie partnership and robust pipeline progress, demonstrate Glenmark's transition from a generic-focused to an innovation-driven pharma company, which could positively influence investor sentiment.